Shukra Pharmaceuticals Limited (BOM:524632)
India · Delayed Price · Currency is INR 41.51
+0.08 (0.19%)
At close: Aug 17, 2026
Shukra Pharmaceuticals Financials Overview
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
| Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Revenue Revenue Growth | 748.59 | 567.27 | 325.87 | 745.73 | 594.93 | 204.86 |
Revenue Growth | 91.91% | 74.08% | -56.30% | 25.35% | 190.41% | 82.97% |
Gross Profit Gross Profit Growth | 613.15 | 408.78 | 242.95 | 300.39 | 140.68 | 99.69 |
Operating Income Operating Income Growth | 468.4 | 298.8 | 124.52 | 196.09 | 46.59 | 12.73 |
Net Income Net Income Growth | 339.87 | 220.58 | 95.75 | 185.37 | 44.07 | 7.51 |
Earnings Per Share EPS Growth | 0.81 | 0.50 | 0.22 | 0.42 | 0.66 | 0.12 |
EPS Growth | 262.37% | 128.66% | -48.35% | -35.38% | 446.67% | 299.10% |
| Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Cash & Investments Cash & Investments Growth | 59.76 | 59.76 | 121.18 | 99.8 | 39.73 | 2.9 |
Total Debt Total Debt Growth | 50.2 | 50.2 | 41.77 | 31.54 | 50.82 | 33.77 |
Net Cash (Debt) Net Cash Growth | 9.57 | 9.57 | 79.41 | 68.27 | -11.09 | -30.87 |
Net Cash Growth | -87.95% | -87.95% | 16.33% | - | - | - |
Net Cash Per Share Net Cash Per Share Growth | 0.02 | 0.02 | 0.18 | 0.16 | -0.16 | -0.49 |
| Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Operating Cash Flow Operating Cash Flow Growth | - | 39.31 | 79.18 | -51.97 | 31.7 | 79.89 |
Capital Expenditures CapEx Growth | - | -157.3 | -27.43 | -17.6 | -44.91 | -15.5 |
Free Cash Flow Free Cash Flow Growth | - | -117.99 | 51.75 | -69.57 | -13.22 | 64.39 |
Free Cash Flow Growth | - | - | - | - | - | - |
| Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Gross Margin | 81.91% | 72.06% | 74.55% | 40.28% | 23.65% | 48.66% |
Operating Margin | 62.57% | 52.67% | 38.21% | 26.30% | 7.83% | 6.21% |
Pretax Margin | 60.90% | 50.75% | 40.93% | 26.66% | 7.47% | 4.97% |
Profit Margin | 45.40% | 38.88% | 29.38% | 24.86% | 7.41% | 3.66% |
FCF Margin | - | -20.80% | 15.88% | -9.33% | -2.22% | 31.43% |
| Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
| Period Ending | Aug '26 Aug 17, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Dividend Per Share Dividend Per Share Growth | 0.010 | 0.010 | 0.010 | 0.100 | 0.013 | 0.013 |
Dividend Per Share Growth | -90.00% | 0% | -90.00% | 700.00% | 0% | - |
Dividend Yield | 0.02% | 0.03% | 0.05% | 1.24% | 1.09% | 4.06% |
| Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
| Period Ending | Aug '26 Aug 17, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
PE Ratio | 51.35 | 60.23 | 99.92 | 19.28 | 11.67 | 12.60 |
P/FCF Ratio | - | - | 184.87 | - | - | 1.47 |
PS Ratio | 24.38 | 23.42 | 29.36 | 4.79 | 0.87 | 0.46 |